CA3117568A1 - Methods for selection and stimulation of cells and apparatus for same - Google Patents
Methods for selection and stimulation of cells and apparatus for same Download PDFInfo
- Publication number
- CA3117568A1 CA3117568A1 CA3117568A CA3117568A CA3117568A1 CA 3117568 A1 CA3117568 A1 CA 3117568A1 CA 3117568 A CA3117568 A CA 3117568A CA 3117568 A CA3117568 A CA 3117568A CA 3117568 A1 CA3117568 A1 CA 3117568A1
- Authority
- CA
- Canada
- Prior art keywords
- cells
- stimulatory
- agent
- ser
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4211—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4214—Receptors for cytokines
- A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5002—Partitioning blood components
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2321—Interleukin-21 (IL-21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/505—CD4; CD8
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/52—CD40, CD40-ligand (CD154)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862753911P | 2018-10-31 | 2018-10-31 | |
| US62/753,911 | 2018-10-31 | ||
| US201962842511P | 2019-05-02 | 2019-05-02 | |
| US62/842,511 | 2019-05-02 | ||
| US201962861314P | 2019-06-13 | 2019-06-13 | |
| US62/861,314 | 2019-06-13 | ||
| PCT/EP2019/079746 WO2020089343A1 (en) | 2018-10-31 | 2019-10-30 | Methods for selection and stimulation of cells and apparatus for same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3117568A1 true CA3117568A1 (en) | 2020-05-07 |
Family
ID=68461775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3117568A Pending CA3117568A1 (en) | 2018-10-31 | 2019-10-30 | Methods for selection and stimulation of cells and apparatus for same |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12522660B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3874024A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7582940B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102912482B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN113227358A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019370705B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021008133A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3117568A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL282757A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021005013A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202104355SA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020089343A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201404991YA (en) | 2012-02-23 | 2014-09-26 | Stage Cell Therapeutics Gmbh | Chromatographic isolation of cells and other complex biological materials |
| RS62471B1 (sr) | 2014-04-16 | 2021-11-30 | Juno Therapeutics Gmbh | Metode, kompleti i uređaji za proširenje populacije ćelija |
| RU2761555C2 (ru) | 2015-10-22 | 2021-12-09 | Джуно Терапьютикс Гмбх | Способы, наборы, средства и устройства для трансдукции |
| MA45489A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés de culture de cellules, kits et appareil associés |
| KR102908806B1 (ko) | 2015-10-22 | 2026-01-07 | 주노 테라퓨틱스 게엠베하 | 세포의 배양 방법 및 이를 위한 키트와 장치 |
| AU2018260380B2 (en) | 2017-04-27 | 2025-02-13 | Juno Therapeutics Gmbh | Oligomeric particle reagents and methods of use thereof |
| BR112021002390A2 (pt) | 2018-08-09 | 2021-05-11 | Juno Therapeutics Inc | processos para gerar células modificadas e suas composições |
| US20220412954A1 (en) | 2019-11-05 | 2022-12-29 | Juno Therapeutics, Inc. | Methods of determining attributes of therapeutic t cell compositions |
| EP4178590A4 (en) * | 2020-07-09 | 2024-09-25 | The Board of Trustees of the Leland Stanford Junior University | MULTIPARALLEL ANALYSIS OF T-CELL THERAPIES |
| CN117916256A (zh) * | 2021-05-06 | 2024-04-19 | 朱诺治疗学有限公司 | 用于刺激和转导t细胞的方法 |
| WO2023278553A1 (en) * | 2021-07-01 | 2023-01-05 | Kite Pharma, Inc. | Closed-system and method for autologous and allogeneic cell therapy manufacturing |
| EP4428229A4 (en) * | 2021-11-02 | 2026-03-25 | Agc Inc | CAR-T LYMPHOCYTE MANUFACTURING PROCESS |
| US20250297282A1 (en) | 2022-05-05 | 2025-09-25 | Juno Therapeutics Gmbh | Viral-binding protein and related reagents, articles, and methods of use |
| WO2024100604A1 (en) | 2022-11-09 | 2024-05-16 | Juno Therapeutics Gmbh | Methods for manufacturing engineered immune cells |
| CN121100267A (zh) | 2022-12-09 | 2025-12-09 | 朱诺治疗学股份有限公司 | 使用全息成像预测细胞表型的机器学习方法 |
| CN115625624B (zh) * | 2022-12-21 | 2023-03-17 | 太原理工大学 | 一种用于清理铸造机匣复杂型腔的装置 |
| US20260232729A1 (en) | 2023-02-03 | 2026-08-13 | C3S2 Gmbh | Methods for non-viral manufacturing of engineered immune cells |
| CN119193479B (zh) * | 2024-11-27 | 2025-02-25 | 四川百科美生物科技有限公司 | 一种间充质干细胞培养多孔微载体及其制备方法和应用 |
Family Cites Families (258)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1631788A (en) | 1926-05-28 | 1927-06-07 | Scovill Manufacturing Co | Condenser-operating mechanism for variable condensers |
| US2467434A (en) | 1947-05-10 | 1949-04-19 | Air Associates Inc | Servomotor and pressure responsive valve therefor |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4361549A (en) | 1979-04-26 | 1982-11-30 | Ortho Pharmaceutical Corporation | Complement-fixing monoclonal antibody to human T cells, and methods of preparing same |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JP2624470B2 (ja) | 1984-10-02 | 1997-06-25 | バイオジェン インコーポレイテッド | ストレプトアビジン様ポリペプチドの製造 |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| IN165717B (cg-RX-API-DMAC7.html) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
| US4851341A (en) | 1986-12-19 | 1989-07-25 | Immunex Corporation | Immunoaffinity purification system |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| US4966695A (en) | 1988-02-04 | 1990-10-30 | Henry Joshua | High pressure liquid chromatography column jacket |
| US6303121B1 (en) | 1992-07-30 | 2001-10-16 | Advanced Research And Technology | Method of using human receptor protein 4-1BB |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| ATE159548T1 (de) | 1990-11-13 | 1997-11-15 | Immunex Corp | Bifunktionelle wählbare fusionsgene |
| GB9215540D0 (en) | 1992-07-22 | 1992-09-02 | Celltech Ltd | Protein expression system |
| DE4228458A1 (de) | 1992-08-27 | 1994-06-01 | Beiersdorf Ag | Multicistronische Expressionseinheiten und deren Verwendung |
| DE4237113B4 (de) | 1992-11-03 | 2006-10-12 | "Iba Gmbh" | Peptide und deren Fusionsproteine, Expressionsvektor und Verfahren zur Herstellung eines Fusionsproteins |
| AU6953394A (en) | 1993-05-21 | 1994-12-20 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
| CA2164226C (en) | 1993-06-04 | 2011-02-08 | Carl H. June | Methods for selectively stimulating proliferation of t cells |
| DE4417598A1 (de) | 1994-05-19 | 1995-12-14 | Max Planck Gesellschaft | Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen |
| US7074904B2 (en) | 1994-07-29 | 2006-07-11 | Altor Bioscience Corporation | MHC complexes and uses thereof |
| DK0776339T4 (da) | 1994-07-29 | 2010-05-25 | Sunol Molecular Corp | MHC-komplekser og anvendelser deraf |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| WO1996013593A2 (en) | 1994-10-26 | 1996-05-09 | Procept, Inc. | Soluble single chain t cell receptors |
| WO1996018105A1 (en) | 1994-12-06 | 1996-06-13 | The President And Fellows Of Harvard College | Single chain t-cell receptor |
| US5753499A (en) | 1994-12-23 | 1998-05-19 | New York University | Viral vector complexes having adapters of predefined valence |
| WO1996023879A1 (en) | 1995-01-30 | 1996-08-08 | Terrapin Technologies, Inc. | Glubodies - multiplicities of proteins capable of binding a variety of small molecules |
| WO1996024606A1 (en) | 1995-02-09 | 1996-08-15 | University Of Washington | Modified-affinity streptavidin |
| WO1997011183A1 (en) | 1995-04-11 | 1997-03-27 | Trustees Of Boston University | Streptavidin mutants |
| US5629205A (en) | 1995-05-19 | 1997-05-13 | Allelix Biopharmaceuticals Inc. | Promoters for gene expression |
| US20020150914A1 (en) | 1995-06-30 | 2002-10-17 | Kobenhavns Universitet | Recombinant antibodies from a phage display library, directed against a peptide-MHC complex |
| US6261554B1 (en) | 1995-07-25 | 2001-07-17 | Introgene B.V. | Compositions for targeted gene delivery |
| AR005035A1 (es) | 1995-12-11 | 1999-04-07 | Merck Patent Ges Mit Beschränkter Haftung | Procedimiento para preparar proteinas recombinantes en e. coli, mediante fermentacion con gran concentracion de celulas. |
| US5869270A (en) | 1996-01-31 | 1999-02-09 | Sunol Molecular Corporation | Single chain MHC complexes and uses thereof |
| US5773224A (en) | 1996-02-12 | 1998-06-30 | Grandics; Peter | Immunoselection system for cell elution |
| DE19608753C1 (de) | 1996-03-06 | 1997-06-26 | Medigene Gmbh | Transduktionssystem und seine Verwendung |
| US6451995B1 (en) | 1996-03-20 | 2002-09-17 | Sloan-Kettering Institute For Cancer Research | Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods |
| DE19637718A1 (de) | 1996-04-01 | 1997-10-02 | Boehringer Mannheim Gmbh | Rekombinante inaktive Core-Streptavidin Mutanten |
| ATE186235T1 (de) | 1996-04-24 | 1999-11-15 | Claude Fell | Zelltrennungsvorrichtung für biologische flüssigkeiten wie blut |
| US6022688A (en) | 1996-05-13 | 2000-02-08 | Sequenom, Inc. | Method for dissociating biotin complexes |
| DK0935607T3 (da) | 1996-08-16 | 2004-12-06 | Harvard College | Oplöselige monovalente og multivalente MHC klasse II-fusionsproteiner samt anvendelser deraf |
| US20050003431A1 (en) | 1996-08-16 | 2005-01-06 | Wucherpfennig Kai W. | Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor |
| DE19641876B4 (de) | 1996-10-10 | 2011-09-29 | Iba Gmbh | Streptavidinmuteine |
| CA2283716A1 (en) | 1997-03-14 | 1998-09-17 | Gabriel O. Reznik | Multiflavor streptavidin |
| US6391571B1 (en) | 1997-04-01 | 2002-05-21 | Roche Diagnostics Gmbh | Recombinant inactive avidin mutants |
| AU741130B2 (en) | 1997-09-16 | 2001-11-22 | Oregon Health Sciences University | Recombinant MHC molecules useful for manipulation of antigen-specific T-cells |
| CA2305630C (en) | 1997-10-02 | 2012-11-06 | Sunol Molecular Corporation | Soluble single-chain t-cell receptor proteins |
| US6232445B1 (en) | 1997-10-29 | 2001-05-15 | Sunol Molecular Corporation | Soluble MHC complexes and methods of use thereof |
| US5985658A (en) | 1997-11-14 | 1999-11-16 | Health Research Incorporated | Calmodulin-based cell separation technique |
| BR9908082A (pt) | 1998-02-19 | 2000-10-31 | Harvard College | Proteìna de fusão do complexo de histocompatibilidade principal classe ii, conjugado dos domìnios de ligação do complexo de histocompatibilidade principal multimérico, processos para detectar células t tendo uma especificidade do complexo definido de mhc / peptìdeo, para conferir a um indivìduo imunidade adotiva a um complexo definido de mhc / peptìdeo, para estimular ou ativar as células t reativas a um complexo definido de mhc / peptìdeo, para seletivamente matar células t reativas a um complexo definido de mhc / peptìdeo, para tolerizar um indivìduo humano a um complexo definido de mhc / peptìdeo, e, ácido nucleico isolado |
| NZ507886A (en) | 1998-05-19 | 2003-05-30 | Avidex Ltd | Multivalent T cell receptor complexes |
| WO1999061065A1 (en) | 1998-05-23 | 1999-12-02 | Leiden University Medical Center | Cd40 binding molecules and ctl peptides for treating tumors |
| WO2000014257A1 (en) | 1998-09-04 | 2000-03-16 | Sloan-Kettering Institute For Cancer Research | Fusion receptors specific for prostate-specific membrane antigen and uses thereof |
| AU2472400A (en) | 1998-10-20 | 2000-05-08 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| ES2224726T3 (es) | 1998-12-24 | 2005-03-01 | Biosafe S.A. | Sistema de separacion sanguinea indicado en particular para la concentracion de celulas madre hematopoyeticas. |
| US6664042B1 (en) | 1999-01-26 | 2003-12-16 | Cornell Research Foundation, Inc. | Determining viral load in double negative T cells |
| MXPA01007820A (es) | 1999-02-04 | 2003-06-19 | Technion Res & Dev Foundation | Metodo y aparato para mantenimiento y expansion de celulas de tallo hemopoyeticas y/o celulas progenitoras. |
| EP1048732A1 (de) | 1999-04-26 | 2000-11-02 | F. Hoffmann-La Roche Ag | Verfahren zur Herstellung von natürlich gefalteten und sekretierten Proteinen |
| US6849185B1 (en) | 1999-05-14 | 2005-02-01 | Pall Corp | Charged membrane |
| DE60027291T2 (de) | 1999-05-14 | 2007-01-18 | Pall Corp. | Elektrisch geladene membran |
| EP1669129A1 (en) | 1999-05-14 | 2006-06-14 | Pall Corporation | Charged membrane |
| ATE458818T1 (de) | 1999-06-07 | 2010-03-15 | Tet Systems Holding Gmbh & Co | Tet repressor basierte transkriptionale regulatorische proteine |
| DE19932688B4 (de) | 1999-07-13 | 2009-10-08 | Scil Proteins Gmbh | Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen |
| MXPA02007473A (es) | 2000-02-01 | 2003-09-22 | Tanox Inc | Moleculas activadoras de celulas presentadoras de antigenos (apc) que se unen a cd40. |
| US20030235908A1 (en) | 2000-02-24 | 2003-12-25 | Xcyte Therapies, Inc. | Activation and expansion of cells |
| US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
| DE60127113T2 (de) | 2000-04-25 | 2007-06-14 | Otsuka Pharmaceutical Co., Ltd. | Gd3-mimetische peptide |
| CA2410510A1 (en) | 2000-06-02 | 2001-12-13 | Memorial Sloan-Kettering Cancer Center | Artificial antigen presenting cells and methods of use thereof |
| US6638728B1 (en) | 2000-06-16 | 2003-10-28 | Pierce Biotechnology, Inc. | Coated surfaces with high capacity for capturing target molecules |
| DK1332222T3 (da) | 2000-11-03 | 2009-07-06 | Genentech Inc | Stofskifteændringer i fermenteringer der udtrykker rekombinante proteiner |
| US7446179B2 (en) | 2000-11-07 | 2008-11-04 | City Of Hope | CD19-specific chimeric T cell receptor |
| US6979556B2 (en) | 2000-12-14 | 2005-12-27 | Genentech, Inc. | Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes |
| EP1227321A1 (en) | 2000-12-28 | 2002-07-31 | Institut für Bioanalytik GmbH | Reversible MHC multimer staining for functional purification of antigen-specific T cells |
| WO2002055992A2 (en) | 2001-01-12 | 2002-07-18 | Becton Dickinson Co | Intrinsically fluorescent, self-multimerizing mhc fusion proteins and complexes thereof |
| GB0102568D0 (en) | 2001-02-01 | 2001-03-21 | Magnetic Biosolutions Sweden A | Method |
| DE10113776B4 (de) | 2001-03-21 | 2012-08-09 | "Iba Gmbh" | Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| EP1908769A1 (en) | 2001-08-27 | 2008-04-09 | Genentech, Inc. | A system for antibody expression and assembly |
| EP1427744B1 (en) | 2001-08-27 | 2007-12-26 | Genentech, Inc. | A system for antibody expression and assembly |
| PT1421115E (pt) | 2001-08-31 | 2005-07-29 | Avidex Ltd | Receptor de celulas t soluvel |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| US7939059B2 (en) | 2001-12-10 | 2011-05-10 | California Institute Of Technology | Method for the generation of antigen-specific lymphocytes |
| US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
| US7094579B2 (en) | 2002-02-13 | 2006-08-22 | Xoma Technology Ltd. | Eukaryotic signal sequences for prokaryotic expression |
| AU2003216341A1 (en) | 2002-02-20 | 2003-09-09 | Dyax Corporation | Mhc-peptide complex binding ligands |
| US8076452B2 (en) | 2002-03-01 | 2011-12-13 | Erdmann Volker A | Streptavidin-binding peptide |
| US20030170238A1 (en) | 2002-03-07 | 2003-09-11 | Gruenberg Micheal L. | Re-activated T-cells for adoptive immunotherapy |
| US7754155B2 (en) | 2002-03-15 | 2010-07-13 | Ross Amelia A | Devices and methods for isolating target cells |
| US20050271653A1 (en) | 2002-04-23 | 2005-12-08 | Meir Strahilevitz | Methods and devices for targeting a site in a mammal and for removing species from a mammal |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| WO2007001459A2 (en) | 2004-11-15 | 2007-01-04 | Washington University | Compositions and methods for modulating lymphocyte activity |
| DE50305695D1 (de) | 2002-06-24 | 2006-12-28 | Profos Ag | Verfahren zum nachweis und zur entfernung von endotoxin |
| FR2841905B1 (fr) | 2002-07-05 | 2004-09-03 | Centre Nat Rech Scient | Fragments fab mutants de l'anticorps anti-cd4 chimere 13b8.2 et leurs applications |
| AU2003246690B2 (en) | 2002-07-17 | 2010-03-11 | Cytos Biotechnology Ag | Molecular antigen arrays using a virus like particle derived from the AP205 coat protein |
| GB2392158B (en) | 2002-08-21 | 2005-02-16 | Proimmune Ltd | Chimeric MHC protein and oligomer thereof |
| EP1569510B1 (en) | 2002-09-27 | 2011-11-02 | The General Hospital Corporation | Microfluidic device for cell separation and uses thereof |
| AU2003271904B2 (en) | 2002-10-09 | 2009-03-05 | Adaptimmune Limited | Single chain recombinant T cell receptors |
| AU2004204462B2 (en) | 2003-01-09 | 2012-03-08 | Macrogenics, Inc. | Dual expression vector system for antibody expression in bacterial and mammalian cells |
| US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
| EP1641911A2 (en) | 2003-05-02 | 2006-04-05 | Insception Bioscience, Inc. | Apparatus and methods for amplification of blood stem cell numbers |
| WO2004104185A1 (en) | 2003-05-08 | 2004-12-02 | Xcyte Therapies, Inc. | Generation and isolation of antigen-specific t cells |
| US7362449B2 (en) | 2003-05-16 | 2008-04-22 | Universite Libre De Bruxelles | Digital holographic microscope for 3D imaging and process using it |
| US7943393B2 (en) | 2003-07-14 | 2011-05-17 | Phynexus, Inc. | Method and device for extracting an analyte |
| SI1656455T1 (sl) | 2003-08-13 | 2012-12-31 | Sandoz Ag | Postopek za čiščenje rekombinantnih polipeptidov |
| GB0319601D0 (en) | 2003-08-20 | 2003-09-24 | Sandoz Ag | Production process |
| GB0321100D0 (en) | 2003-09-09 | 2003-10-08 | Celltech R&D Ltd | Biological products |
| GB2408507B (en) | 2003-10-06 | 2005-12-14 | Proimmune Ltd | Chimeric MHC protein and oligomer thereof for specific targeting |
| KR100570422B1 (ko) | 2003-10-16 | 2006-04-11 | 한미약품 주식회사 | 대장균 분비서열을 이용하여 항체 단편을 분비·생산하는 발현벡터 및 이를 이용하여 항체 단편을 대량 생산하는 방법 |
| US20080050795A1 (en) | 2003-11-20 | 2008-02-28 | Biosensor Applications Sweden Ab | Mixture Of At Least Two Different Antibodies Specific For Predetermined Antigens And Use Of The Mixture |
| BRPI0416807A (pt) | 2003-11-21 | 2007-01-09 | Dow Global Technologies Inc | sistemas de expressão aperfeiçoados com secreção de sistema sec |
| SE0400181D0 (sv) | 2004-01-29 | 2004-01-29 | Gyros Ab | Segmented porous and preloaded microscale devices |
| BRPI0507233B8 (pt) | 2004-03-11 | 2021-05-25 | Genentech Inc | processo para a produção de um polipeptídeo heterólogo em e. coli |
| US20090304679A1 (en) | 2004-05-27 | 2009-12-10 | Weidanz Jon A | Antibodies as T cell receptor mimics, methods of production and uses thereof |
| US20060034850A1 (en) | 2004-05-27 | 2006-02-16 | Weidanz Jon A | Antibodies as T cell receptor mimics, methods of production and uses thereof |
| US20090226474A1 (en) | 2004-05-27 | 2009-09-10 | Weidanz Jon A | Antibodies as T cell receptor mimics, methods of production and uses thereof |
| EP1766400B1 (en) | 2004-06-03 | 2009-04-15 | Meso Scale Technologies, LLC | Methods for conducting whole blood assays |
| EP1791865B1 (en) | 2004-06-29 | 2010-07-28 | Immunocore Ltd. | Cells expressing a modified t cell receptor |
| GB2435760B (en) | 2004-10-07 | 2010-07-14 | Waters Investments Ltd | HPLC Capillary Column Cartridge Cassette |
| JP5255841B2 (ja) | 2004-10-15 | 2013-08-07 | ジェネンコー・インターナショナル・インク | 競合示差スクリーニング |
| EP1812465B1 (en) | 2004-11-12 | 2016-09-07 | Genentech, Inc. | Novel composition and methods for the treatment of immune related diseases |
| WO2006058226A2 (en) | 2004-11-24 | 2006-06-01 | The Trustees Of Boston University | Modified dimeric streptavidins and uses thereof |
| US20060252087A1 (en) | 2005-01-18 | 2006-11-09 | Biocept, Inc. | Recovery of rare cells using a microchannel apparatus with patterned posts |
| US20080171951A1 (en) | 2005-03-23 | 2008-07-17 | Claude Fell | Integrated System for Collecting, Processing and Transplanting Cell Subsets, Including Adult Stem Cells, for Regenerative Medicine |
| BRPI0616446A2 (pt) | 2005-09-28 | 2011-06-21 | Cytos Biotechnology Ag | composição contendo conjugados de interleucina-1, vacina, uso da vacina, composição farmacêutica, processo para a produção da composição ou da vacina, bem como medicamento |
| US7704708B2 (en) | 2006-02-13 | 2010-04-27 | Uti Limited Partnership | Monomeric streptavidin muteins |
| US7855057B2 (en) | 2006-03-23 | 2010-12-21 | Millipore Corporation | Protein splice variant/isoform discrimination and quantitative measurements thereof |
| WO2007117602A2 (en) | 2006-04-07 | 2007-10-18 | Biogen Idec Ma Inc. | Isolation and use of human regulatory t cells |
| US20070238169A1 (en) | 2006-04-11 | 2007-10-11 | The Board Of Trustees Of The Leland Stanford Junior University | Cell sorter and culture system |
| US20100005867A1 (en) | 2006-07-17 | 2010-01-14 | Agilent Technologies, Inc. | Temperature adjustment of a fluidic sample within a fluidic device |
| GB2442048B (en) | 2006-07-25 | 2009-09-30 | Proimmune Ltd | Biotinylated MHC complexes and their uses |
| US20080085532A1 (en) | 2006-09-18 | 2008-04-10 | Jorn Gorlach | Method for determining the immune status of a subject |
| EP1905839B2 (de) | 2006-09-22 | 2019-07-10 | Wacker Chemie AG | Verfahren zur fermentativen Herstellung von Proteinen |
| DK1903115T3 (da) | 2006-09-22 | 2011-05-23 | Wacker Chemie Ag | Fremgangsmåde til fermentativ fremstilling af antistoffer |
| EP1903105B1 (de) | 2006-09-22 | 2010-04-21 | Wacker Chemie AG | Verfahren zur fermentativen Herstellung von Proteinen |
| DE102006044841A1 (de) | 2006-09-22 | 2008-04-03 | Wacker Chemie Ag | Signalpeptid zur Produktion von rekombinanten Proteinen |
| CA2915560A1 (en) | 2006-10-17 | 2008-04-24 | Tomoaki Fujioka | Peptide vaccines for cancers expressing mphosph1 or depdc1 polypeptides |
| GB0620894D0 (en) | 2006-10-20 | 2006-11-29 | Univ Southampton | Human immune therapies using a CD27 agonist alone or in combination with other immune modulators |
| CA2668001C (en) | 2006-11-02 | 2016-05-03 | Kyowa Medex Co., Ltd. | A method of immunoassaying a component to be measured in a sample containing hemoglobin |
| US20080255004A1 (en) | 2006-11-15 | 2008-10-16 | Invitrogen Dynal As | Methods of reversibly binding a biotin compound to a support |
| CN101226118B (zh) | 2007-01-19 | 2010-06-16 | 中国医学科学院肿瘤研究所 | 一种兼容免疫荧光分析的细胞化学染色方法及其用途 |
| KR101491867B1 (ko) | 2007-01-31 | 2015-02-10 | 피페넥스 인크. | 증가된 발현을 위한 박테리아 리더 서열 |
| KR20080076622A (ko) | 2007-02-16 | 2008-08-20 | 포항공과대학교 산학협력단 | 올리고머화된 단백질 전달체와 이를 이용한 세포내바이러스 벡터 전달 방법 |
| EP2617827A1 (en) | 2007-03-26 | 2013-07-24 | Celexion, LLC | Method for displaying engineered proteins on a cell surface |
| EP2155782A2 (en) | 2007-03-26 | 2010-02-24 | Dako Denmark A/S | Mhc peptide complexes and uses thereof in infectious diseases |
| US8389282B2 (en) | 2007-03-30 | 2013-03-05 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes |
| BRPI0811466A2 (pt) | 2007-05-07 | 2014-10-14 | Medimmune Llc | Anticorpo anti-icos isolado, ácido nucleico, vetor, célula isolada, métodos para produzir um anticorpo, para tratar uma doença ou distúrbio, para tratar ou prevenir a rejeição em um paciente de transplante humano, para tratar uma malignidade de célula t em um ser humano, para esgotar células t que expressam icos em um paciente humano, para romper a arquitetura do centro germinal em um órgão linfóide secundário de um primata, para esgotar células b centrais germinais de órgão linfóide secundário de um primata, e para esgotar células b comutadas em classes circulantes em um primata, e, composição farmacêutica. |
| WO2009003493A2 (en) | 2007-07-03 | 2009-01-08 | Dako Denmark A/S | Mhc multimers, methods for their generation, labeling and use |
| EP2193199B1 (en) | 2007-08-20 | 2013-11-06 | Nextera AS | Pvii phage display |
| ES2319061B1 (es) | 2007-09-11 | 2010-02-10 | Biomedal, S.L. | Metodo de conservacion de peptidos o proteinas. |
| WO2009039854A2 (en) | 2007-09-27 | 2009-04-02 | Dako Denmark A/S | Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics |
| EP2520643B8 (en) | 2007-12-07 | 2019-11-27 | Miltenyi Biotec B.V. & Co. KG | Sample processing systems and methods |
| US8479118B2 (en) | 2007-12-10 | 2013-07-02 | Microsoft Corporation | Switching search providers within a browser search box |
| SG10201704689XA (en) | 2008-01-18 | 2017-07-28 | Harvard College | Methods of detecting signatures of disease or conditions in bodily fluids |
| EP2245054B1 (en) | 2008-01-30 | 2018-11-28 | Pieris Pharmaceuticals GmbH | Muteins of tear lipocalin having affinity to human c-met receptor tyrosine kinase and methods for obtaining the same |
| WO2009106073A2 (en) | 2008-02-28 | 2009-09-03 | Dako Denmark A/S | Mhc multimers in borrelia diagnostics and disease |
| JP5173594B2 (ja) | 2008-05-27 | 2013-04-03 | キヤノン株式会社 | 管理装置、画像形成装置及びそれらの処理方法 |
| CA2735456C (en) | 2008-08-26 | 2021-11-16 | City Of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| WO2010037395A2 (en) | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
| CN101446576B (zh) | 2008-12-29 | 2011-06-22 | 江苏省苏微微生物研究有限公司 | 一种微囊藻毒素-lr单抗免疫亲和柱的制备和使用方法 |
| WO2010080032A2 (en) | 2009-01-09 | 2010-07-15 | Stichting Het Nederlands Kanker Instituut | Bead-assisted viral transduction |
| CN102421801B (zh) | 2009-03-10 | 2016-03-16 | 比奥根Ma公司 | 抗-bcma抗体 |
| DE102009018647A1 (de) | 2009-04-23 | 2010-10-28 | Osram Opto Semiconductors Gmbh | Strahlungsemittierende Vorrichtung |
| US20110070581A1 (en) | 2009-04-27 | 2011-03-24 | Amit Gupta | Separation of Leukocytes |
| WO2011044186A1 (en) | 2009-10-06 | 2011-04-14 | The Board Of Trustees Of The University Of Illinois | Human single-chain t cell receptors |
| WO2011053971A2 (en) | 2009-11-02 | 2011-05-05 | Fina Biosolutions, Llc | Method for enhancing the sensitivity of antibody based assays |
| JP5956342B2 (ja) | 2009-11-03 | 2016-07-27 | シティ・オブ・ホープCity of Hope | 形質導入T細胞選択のためのトランケート上皮増殖因子レセプタ(EGFRt) |
| KR101968766B1 (ko) | 2009-11-05 | 2019-04-12 | 제넨테크, 인크. | 이종 폴리펩티드의 분비를 위한 방법 및 조성물 |
| CN104531734A (zh) | 2009-11-17 | 2015-04-22 | 詹森生物科技公司 | 改善的细菌膜蛋白分泌 |
| US20120321665A1 (en) | 2009-12-14 | 2012-12-20 | Benaroya Research Institute At Virginia Mason | Compositions and methods for treating airway inflammatory diseases |
| US9370732B2 (en) | 2013-02-15 | 2016-06-21 | Douglas T. Gjerde | Methods for purifying biological cells |
| US9242244B2 (en) | 2010-02-09 | 2016-01-26 | Douglas T. Gjerde | Method and apparatus for pipette tip columns |
| US9637719B2 (en) | 2013-12-06 | 2017-05-02 | Douglas T. Gjerde | Devices and methods for purification of biological cells |
| US9891148B2 (en) | 2010-02-09 | 2018-02-13 | Douglas T. Gjerde | Method and apparatus for pipette tip columns |
| GB201002730D0 (en) | 2010-02-18 | 2010-04-07 | Uni I Oslo | Product |
| EP2363501A1 (en) | 2010-03-02 | 2011-09-07 | Universitätsklinikum Hamburg-Eppendorf | Method for isolating target cells |
| JP5665021B2 (ja) | 2010-03-08 | 2015-02-04 | 国立大学法人東京農工大学 | 融合mhc分子連結磁気微粒子、抗原ペプチドのスクリーニング方法、組換えベクター、及び磁性細菌の形質転換体 |
| WO2011130617A2 (en) | 2010-04-15 | 2011-10-20 | Smartflow Technologies, Inc. | An integrated bioreactor and separation system and methods of use thereof |
| US9677038B2 (en) | 2010-06-23 | 2017-06-13 | Strobbe Pharma Tech Gmbh | Device and method for industrial cultivation of cells |
| GB201012603D0 (en) | 2010-07-27 | 2010-09-08 | Ucb Pharma Sa | Protein purification |
| US9410157B2 (en) | 2010-07-30 | 2016-08-09 | Wisconsin Alumni Research Foundation | Systems and methods for the secretion of recombinant proteins in gram negative bacteria |
| EP2601521B1 (en) | 2010-08-06 | 2018-05-02 | Ludwig-Maximilians-Universität München | Identification of t cell target antigens |
| US10023657B2 (en) | 2010-10-01 | 2018-07-17 | Ludwig Institute For Cancer Research Ltd. | Reversible protein multimers, methods for their production and use |
| WO2012058627A2 (en) | 2010-10-29 | 2012-05-03 | Miqin Zhang | Pre-targeted nanoparticle system and method for labeling biological particles |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| JP5897035B2 (ja) | 2010-12-14 | 2016-03-30 | ユニバーシティ オブ メリーランド,ボルチモア | 汎用の抗タグキメラ抗原受容体発現t細胞及びがんを治療する方法 |
| WO2012129514A1 (en) | 2011-03-23 | 2012-09-27 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| ES2785081T3 (es) | 2011-04-01 | 2020-10-05 | Memorial Sloan Kettering Cancer Center | Anticuerpos biespecíficos similares a receptores de células T específicos para un péptido de WT1 presentado por HLA-A2 |
| JP5840857B2 (ja) | 2011-04-08 | 2016-01-06 | 国立大学法人 東京大学 | 細胞傷害性t細胞誘導用組成物 |
| US8398282B2 (en) | 2011-05-12 | 2013-03-19 | Delphi Technologies, Inc. | Vehicle front lighting assembly and systems having a variable tint electrowetting element |
| ES2682750T5 (en) | 2011-07-18 | 2025-02-04 | Iba Lifesciences Gmbh | Method of reversibly staining a target cell |
| KR20160103175A (ko) | 2011-07-19 | 2016-08-31 | 오비지오 이미징 시스템스 엔.브이. | 세포 샘플에서의 암 세포들의 검출 및/또는 분류를 위한 방법 및 시스템 |
| US9353161B2 (en) | 2011-09-13 | 2016-05-31 | Uti Limited Partnership | Streptavidin mutein exhibiting reversible binding for biotin and streptavidin binding peptide tagged proteins |
| GB201116092D0 (en) | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
| WO2013062365A2 (ko) | 2011-10-26 | 2013-05-02 | 국립암센터 | 변이 ctla4 유전자 이입 t 세포 및 이를 포함하는 항암 면역치료용 조성물 |
| WO2013071154A1 (en) | 2011-11-11 | 2013-05-16 | Fred Hutchinson Cancer Research Center | Cyclin a1-targeted t-cell immunotherapy for cancer |
| EP2814846B1 (en) | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
| SG11201404991YA (en) | 2012-02-23 | 2014-09-26 | Stage Cell Therapeutics Gmbh | Chromatographic isolation of cells and other complex biological materials |
| NZ702108A (en) | 2012-05-03 | 2016-09-30 | Hutchinson Fred Cancer Res | Enhanced affinity t cell receptors and methods for making the same |
| US11185795B2 (en) | 2012-07-06 | 2021-11-30 | Waters Technologies Corporation | Techniques for thermally insulating a chromatographic column |
| DE112013003406T5 (de) | 2012-07-06 | 2015-09-03 | Waters Technologies Corporation | Verfahren zur Beschleunigung des thermischen Gleichgewichts in einer Chromatographiesäule |
| US10413846B2 (en) | 2012-07-06 | 2019-09-17 | Waters Technologies Corporation | Techniques for thermally insulating a liquid chromatographic column |
| UA114108C2 (uk) | 2012-07-10 | 2017-04-25 | Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем | Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання |
| KR20210149195A (ko) | 2012-07-13 | 2021-12-08 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 형질도입된 t 세포의 투여 적합성을 평가하는 방법 |
| LT2884999T (lt) | 2012-08-20 | 2021-04-12 | Fred Hutchinson Cancer Research Center | Ląstelinės imunoterapijos būdas ir kompozicijos |
| EP2898310B1 (en) | 2012-09-20 | 2019-05-01 | Ovizio Imaging Systems NV/SA | Digital holographic microscope with fluid systems |
| EP2711418B1 (en) | 2012-09-25 | 2017-08-23 | Miltenyi Biotec GmbH | Method for polyclonal stimulation of T cells by flexible nanomatrices |
| RU2729401C2 (ru) | 2012-10-02 | 2020-08-06 | Мемориал Слоан-Кеттеринг Кэнсер Сентер | Композиции и способы для иммунотерапии |
| EP2920204B1 (en) | 2012-11-16 | 2019-09-18 | IBA GmbH | Streptavidin muteins and methods of using them |
| JP2016504918A (ja) | 2013-01-31 | 2016-02-18 | グラクソ グループ リミテッドGlaxo Group Limited | タンパク質を製造する方法 |
| US10107729B2 (en) | 2013-02-15 | 2018-10-23 | Douglas T. Gjerde | Isolation, detection and use of biological cells |
| US10220332B2 (en) | 2013-02-15 | 2019-03-05 | Douglas T. Gjerde | Columns for isolation, detection and use of biological cells |
| US9920294B2 (en) | 2013-02-15 | 2018-03-20 | Douglas T. Gjerde | Devices and methods for purification, detection and use of biological cells |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| CN103305464B (zh) | 2013-06-05 | 2015-04-15 | 南昌大学 | 直接分离cd4+和cd8+淋巴细胞的方法 |
| NZ759969A (en) | 2013-12-20 | 2022-12-23 | Fred Hutchinson Cancer Center | Tagged chimeric effector molecules and receptors thereof |
| RS62471B1 (sr) | 2014-04-16 | 2021-11-30 | Juno Therapeutics Gmbh | Metode, kompleti i uređaji za proširenje populacije ćelija |
| IL292038B2 (en) | 2014-04-23 | 2024-12-01 | Juno Therapeutics Inc | Methods for enriching or producing immune cell populations for adoptive therapy |
| JP6661544B2 (ja) | 2014-04-24 | 2020-03-11 | ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング | 遺伝子改変したt細胞の自動生成法 |
| CN106662584B (zh) | 2014-04-30 | 2020-05-05 | Iba股份有限公司 | 分离靶细胞的方法 |
| EP3166968B1 (en) | 2014-05-02 | 2021-09-22 | The Trustees of the University of Pennsylvania | Compositions and methods of chimeric autoantibody receptor t cells |
| CA2956385A1 (en) | 2014-07-25 | 2016-01-28 | Theravectys | Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule |
| TWI751102B (zh) | 2014-08-28 | 2022-01-01 | 美商奇諾治療有限公司 | 對cd19具專一性之抗體及嵌合抗原受體 |
| ES2688035T3 (es) | 2014-08-29 | 2018-10-30 | Gemoab Monoclonals Gmbh | Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes |
| GB201415344D0 (en) | 2014-08-29 | 2014-10-15 | Ucl Business Plc | Protein |
| JP6740234B2 (ja) | 2014-11-05 | 2020-08-12 | ジュノー セラピューティクス インコーポレイテッド | 形質導入および細胞プロセシングのための方法 |
| AU2015357535B2 (en) | 2014-12-05 | 2020-05-14 | Eureka Therapeutics, Inc. | Antibodies targeting G-protein coupled receptor and methods of use |
| CN113698497A (zh) | 2014-12-05 | 2021-11-26 | 纪念斯隆-凯特琳癌症中心 | 靶向b-细胞成熟抗原的嵌合抗原受体及其用途 |
| HRP20210582T1 (hr) | 2014-12-05 | 2021-09-03 | Memorial Sloan Kettering Cancer Center | Antitijela koja ciljaju antigen sazrijevanja b-stanice i postupci uporabe |
| DK3227339T3 (da) | 2014-12-05 | 2022-01-10 | Memorial Sloan Kettering Cancer Center | Kimæriske antigenreceptorer rettet mod g-protein-koblet receptor og anvendelser deraf |
| WO2016166568A1 (en) * | 2015-04-16 | 2016-10-20 | Juno Therapeutics Gmbh | Methods, kits and apparatus for expanding a population of cells |
| KR102908806B1 (ko) * | 2015-10-22 | 2026-01-07 | 주노 테라퓨틱스 게엠베하 | 세포의 배양 방법 및 이를 위한 키트와 장치 |
| MA45489A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés de culture de cellules, kits et appareil associés |
| RU2761555C2 (ru) | 2015-10-22 | 2021-12-09 | Джуно Терапьютикс Гмбх | Способы, наборы, средства и устройства для трансдукции |
| MX2018006789A (es) | 2015-12-03 | 2019-02-13 | Juno Therapeutics Inc | Receptores quimericos modificados y composiciones y metodos relacionados. |
| KR102427334B1 (ko) | 2016-04-01 | 2022-08-03 | 카이트 파마 인코포레이티드 | 키메라 항원 및 t 세포 수용체 및 사용 방법 |
| AU2017248259A1 (en) | 2016-04-07 | 2018-10-25 | Bluebird Bio, Inc. | Chimeric antigen receptor T cell compositions |
| WO2017180969A2 (en) | 2016-04-15 | 2017-10-19 | Waters Technologies Corporation | Techniques for thermally insulating a chromatographic column |
| US11932870B2 (en) | 2016-12-05 | 2024-03-19 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
| EP3571221A2 (en) | 2017-01-20 | 2019-11-27 | Juno Therapeutics GmbH | Cell surface conjugates and related cell compositions and methods |
| CN110913690A (zh) | 2017-03-14 | 2020-03-24 | 朱诺治疗学股份有限公司 | 用于低温储存的方法 |
| AU2018260380B2 (en) | 2017-04-27 | 2025-02-13 | Juno Therapeutics Gmbh | Oligomeric particle reagents and methods of use thereof |
| US12036241B2 (en) | 2017-07-19 | 2024-07-16 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
| KR102755437B1 (ko) | 2017-08-09 | 2025-01-20 | 주노 쎄러퓨티크스 인코퍼레이티드 | 유전자 조작된 세포 조성물 및 관련 조성물의 제조 방법 |
| EP4516896A3 (en) | 2017-08-09 | 2025-05-14 | Juno Therapeutics, Inc. | Methods and compositions for preparing genetically engineered cells |
| CA3080509A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Process for producing a t cell composition |
| AU2018379091A1 (en) | 2017-12-08 | 2020-06-25 | Juno Therapeutics, Inc. | Serum-free media formulation for culturing cells and methods of use thereof |
| US20190247846A1 (en) | 2018-02-09 | 2019-08-15 | Chris Suh | Method and Apparatus for Pipette Tip Columns |
| CN112585276A (zh) | 2018-04-05 | 2021-03-30 | 朱诺治疗学股份有限公司 | 产生表达重组受体的细胞的方法和相关组合物 |
| BR112021002390A2 (pt) | 2018-08-09 | 2021-05-11 | Juno Therapeutics Inc | processos para gerar células modificadas e suas composições |
| MX2022005145A (es) | 2019-10-30 | 2022-06-29 | Juno Therapeutics Gmbh | Dispositivos de estimulación y/o selección celular y método de uso. |
| US20230090117A1 (en) | 2020-01-28 | 2023-03-23 | Juno Therapeutics, Inc. | Methods for t cell transduction |
| CN117916256A (zh) | 2021-05-06 | 2024-04-19 | 朱诺治疗学有限公司 | 用于刺激和转导t细胞的方法 |
-
2019
- 2019-10-30 WO PCT/EP2019/079746 patent/WO2020089343A1/en not_active Ceased
- 2019-10-30 JP JP2021523658A patent/JP7582940B2/ja active Active
- 2019-10-30 MX MX2021005013A patent/MX2021005013A/es unknown
- 2019-10-30 KR KR1020217015787A patent/KR102912482B1/ko active Active
- 2019-10-30 EP EP19798040.2A patent/EP3874024A1/en active Pending
- 2019-10-30 AU AU2019370705A patent/AU2019370705B2/en active Active
- 2019-10-30 SG SG11202104355SA patent/SG11202104355SA/en unknown
- 2019-10-30 BR BR112021008133-0A patent/BR112021008133A2/pt unknown
- 2019-10-30 US US17/289,690 patent/US12522660B2/en active Active
- 2019-10-30 CN CN201980086177.9A patent/CN113227358A/zh active Pending
- 2019-10-30 CA CA3117568A patent/CA3117568A1/en active Pending
-
2021
- 2021-04-28 IL IL282757A patent/IL282757A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021005013A (es) | 2021-07-21 |
| AU2019370705A1 (en) | 2021-05-27 |
| US20220002669A1 (en) | 2022-01-06 |
| KR20210098450A (ko) | 2021-08-10 |
| JP2022512872A (ja) | 2022-02-07 |
| BR112021008133A2 (pt) | 2021-10-05 |
| AU2019370705B2 (en) | 2026-01-22 |
| KR102912482B1 (ko) | 2026-01-16 |
| US12522660B2 (en) | 2026-01-13 |
| IL282757A (en) | 2021-06-30 |
| WO2020089343A1 (en) | 2020-05-07 |
| SG11202104355SA (en) | 2021-05-28 |
| CN113227358A (zh) | 2021-08-06 |
| JP7582940B2 (ja) | 2024-11-13 |
| EP3874024A1 (en) | 2021-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019370705B2 (en) | Methods for selection and stimulation of cells and apparatus for same | |
| US20260078165A1 (en) | Processes for generating engineered cells and compositions thereof | |
| US20240101613A1 (en) | Oligomeric particle reagents and methods of use thereof | |
| CA3084445A1 (en) | Process for producing a composition of engineered t cells | |
| US20250283037A1 (en) | Methods for stimulating and transducing t cells | |
| AU2020377043B2 (en) | Cell selection and/or stimulation devices and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220913 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20241205 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION Effective date: 20250407 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251020 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251020 |
|
| C11 | Application revival requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-C10-C11-C106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REINSTATEMENT REQUEST RECEIVED Effective date: 20251029 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20251029 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260413 |
|
| C13 | Application revived following an application revival request |
Free format text: ST27 STATUS EVENT CODE: A-6-2-C10-C13-C102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REINSTATEMENT REQUIREMENTS DEEMED COMPLIANT FOR ALL ABANDONMENT REASONS Effective date: 20260509 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260509 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260511 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260519 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260519 |